MetaCap

Scholar Rock Holding Corporation (SRRK)

NASDAQ: SRRKHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

48.13-2.24 (-4.45%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SRRK stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$3.23
52-week range
38.69 – 61.76
Day range
47.94 – 52.17
Volume / Avg
2.08M / 1.86M
Beta
—

52-week range

$38.69$61.76

SRRK stock today

Scholar Rock (SRRK) closed at $48.13 on Nov 20, down 4.45% (-$2.24), versus the S&P 500's 3.70% decline. At this level, SRRK sits in the middle of its 52-week range of $38.69 to $61.76: 22.1% below the high, set on Aug 26, 2026 and 24.4% above the low. SRRK is up 9.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 19.7%.

Scholar Rock has posted a net loss over the last twelve months (EPS of -$3.23), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Scholar Rock

Company profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. David L. Hallal
Headquarters
Cambridge, MA
Employees
289
IPO year
2018

Financial highlights

Full financials

In fiscal 2025, Scholar Rock generated $0 in revenue. Scholar Rock reported a net loss of $377.9 million, compared with a loss of $246.3 million a year earlier. Diluted earnings per share came in at -$3.29.

Scholar Rock annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$0——$33.19M$18.82M
Growth———+76.41%+22.16%
Net income$-377.94M$-246.29M$-165.79M$-134.50M$-131.80M
EPS (diluted)$-3.29$-2.47$-1.99$-2.26$-3.59

Analyst forecast

Forecast

Consensus (18 analysts)

strong_buy

Avg. price target

$70.06+45.56%

  • Strong buy 2
  • Buy 14
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $58.00High $84.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.81 vs $-0.87
Surprise
+6.90%

SRRK news

All SRRK news

Scholar Rock peers

Health Care sector
SRRK peer companies
CompanyPrice% ChgMarket capCompare
KODKodiak Sciences Inc97.17-0.75%$6.35Bvs SRRK
IBRXImmunityBio Inc.6.02-8.37%$6.40Bvs SRRK
IMVTImmunovant Inc.31.77-2.31%$6.57Bvs SRRK
TWSTTwist Bioscience Corporation103.32-7.44%$7.04Bvs SRRK
CGONCG Oncology Inc.79.47-2.97%$7.10Bvs SRRK
ADPTAdaptive Biotechnologies Corporation27.93-0.43%$4.52Bvs SRRK
CRSPCRISPR Therapeutics AG39.10+0.44%$3.79Bvs SRRK
TARSTarsus Pharmaceuticals Inc.73.01-6.00%$3.60Bvs SRRK

Indexes, lists and sector

Scholar Rock stock FAQ

What is Scholar Rock's stock price today?

SRRK last traded at $48.13 as of Nov 20, 4:00 PM EST, down 4.45% on the day. Prices are delayed at least 15 minutes.

Who is Scholar Rock's CEO?

Mr. David L. Hallal is the chief executive officer of Scholar Rock Holding Corporation, which has about 289 employees.

What is the SRRK 52-week high?

The 52-week high for SRRK is $61.76 and the 52-week low is $38.69. The stock is currently 22.1% below its high.

Compare SRRK